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Abstract
The global pharmaceutical business environment has been rapidly changing and has
more competitive. Competition in pharmaceutical industry extended far beyond the
traditional battle field, research and development. Bayer AG, a leading pharmaceutical
company, decided to evaluate lean management as a tool to improve their
competitiveness in the market.
This thesis attempts to understand the system impact of the lean management
implementation to the Bayer supply chain using modeling and simulation tools. The
results of the model will be used to determine the system characteristics of current
practice and lean practice. The objective of this thesis is to use the system
characteristics generated from the simulation models and provide implementation
recommendation to Bayer AG.
Thesis Advisor: David Simchi-Levi
Title: Professor of Civil and Environmental Engineering and Engineering Systems
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Chapter 1: Introduction
1.1 The Pharmaceutical Industry
The pharmaceutical industry is one of the largest industries in the world. Traditionally,
pharmaceutical companies rely heavily on their patents to generate revenue which led to
high concentration of resources in research and development. In 2010, top 15
pharmaceutical companies generated over $476 billion revenue. On average, each
company spends 17.78% of its revenue, approximately $4.3 billion dollars, on research
and development (Table 1).
With so much concentration in R&D, many pharmaceutical companies put less effort in
lean management. In the past two decades, lean management became the hottest topic
in many industries, such as electronic, retail, and automobile. Pharmaceutical industry
also showed interest in lean management, and companies such as Pfizer, Novartis, and
Amgen stated their operational excellence programs earlier this decade.
While there are many publications on successful lean projects by professionals and
researchers, pharmaceutical industry was unable to produce the similar result
comparing to electronics, retail, and automobile industry. The most commonly used
measurement of leanness is the inventory turnover. In the past five years, Wal-mart's
inventory turnover was improved by 15.5%, from 7.7 turns per year in 2005 to 8.9 turns
per year in 2010. In the same period of time, top 15 pharmaceutical companies'
inventory turnover showed an average decrease of 16% (Table 2). The lack of success
on lean implementation was caused by resistant to change, lack of system thinking, and
poor execution.
Pharmaceutical companies have a strong silo effect which communication is not
effective between different functions. Changes are very difficult to implement in this
environment. Without effective communication, system-wide improvement cannot be
achieved. An interview was conducted to employees of two leading pharmaceutical and
biotech companies, and over half of the interviewees did not know the responsibility of
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their upstream or downstream functions. This result will lead to poor project selection
and execution. While pharmaceutical industry falls behind on lean management, the
business environment becomes more competitive.
Sanofi-Aventis $ 40,871 $6,392 $ 40,871 100.00% 15.64%
Novartis $ 38,455 $7,469 $ 44,267 86.87% 19.42%
GlaxoSmithKline $ 36,746 $6,181 $ 44,422 82.72% 16.82%
AstraZeneca $ 31,905 $4,409 $ 32,804 97.26% 13.82%
Merck $ 26,929 $5,845 $ 29,121 92.47% 21.71%
Johnson &
Johnson $ 22,520 $4,591 $ 61,897 36.38% 20.39%
Eli Lilly $ 20,629 $4,327 $ 21,836 94.47% 20.98%
Bristol-Myers
Squibb $ 18,808 $3,647 $ 18,808 100.00% 19.39%
Abbott $ 16,486 $2,743 $ 30,765 53.59% 16.64%
Takeda 14,204.00 $3,195 $ 15,803 89.88% 22.49%
Boehringer- $
Ingelheim 14,027.00 $3,089 $ 17,741 79.07% 22.02%
Teva Pharma $ 13,814 $802 $ 13,899 99.39% 5.81%
Bayer $ 13,344 $2,192 $ 43,468 30.70% 16.43%
Table I Top 15 Pharmaceutical Firm Financials (Yahoo Finance)
In pharmaceutical industry, when patents expired, generic drugs producers can easily
reverse engineer the formula, and then sell it at a much lower price. Teva
Pharmaceutical, a generic drug company, published a study that estimate global
generics market will reach $120 billion dollars in 2012, which will double 2007's market
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share [Teva Pharmaceuticals, 2008]. Teva's study also reviled that over $50 billion worth
of branded drug will reach their patent expiration date by 2013. According to FDA's
Orange Book, 79% of the branded drugs have at least one generic counterpart. Branded
manufacturers have to focus on cost reduction on those drugs with expiring patents in
order to compete with generic drugs.
Merck 2.9 2.3
Johnson & Johnson 3.6 3.6
Eli Lilly 1.7 1.6
Bristol-Myers Squibb
Abbott
2.4
4.1
3.5 1
4.4 1
0.00 1 0.0%
1.10
0.30
1 45.8%
Boehringer-Ingelheim 2.5 1.7
Teva Pharma 2.3 1.94
Bayer 2.6 2.3
Table 2 Inventory Turnover Trends of Top Pharmaceutii
Another way for branded drugs manufactures to compete with generic drugs
manufactures is to invent more new drugs. However, new drug production becomes
more difficult in recent years. In Phrma Profile 2011 report, the median number of
procedures per clinical trial is increased by 49% and the total work burden per protocol
is grew by 54% between year 2000 and 2007 [PhRMA, 2011]. The increase of
regulations resulted in higher R&D cost and longer commercialization process, but
pharmaceutical industry is not the only one slowing down. According to the Ernst &
Young's report [3], there was a clear trend that showed the number of FDA product
approval rate was slowed down dramatically since 1996 (Figure 1). This has become a
15
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1 7.3%1
problem for all non-generic drug producers since they cannot cash-in on their product
until the product label is approved by FDA. To deal with this problem, one of the leading
biotech companies recently implemented lean laboratory to drive down the R&D cost
and the R&D cycle time.
FDA product approvals, 1996-2009
Figure 1 FDA Product Approval Rate (Ernst & Young, 2010)
Another challenge pharmaceutical industry has to face is that the demand for drug is
projected to increase at a much faster pace than capacity. United States, the largest
market for pharmaceutical products, recently changed their healthcare policy. This
change will generate heavy demand. President Obama signed The Health Care Reform
bill, one of the most expensive social legislation, early last year. This legislation carries
many positive and negative implications on the future of pharmaceutical industry.
According to President Obama, this bill will provide health insurance to 32 million
additional Americans and legal residents. As the insurance coverage increases from
83% to the estimated coverage of 95%, the demand for drugs should increase as well.
Country such as China and India will also have high demands as baby-boomers reach
their retirement age. To satisfy the increasing demand while driving down cost,
pharmaceutical industry has to increase their efficiency through lean management.
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1.2 Bayer AG
Bayer AG is a global chemical and pharmaceutical holding company headquartered in
Leverkusen, Germany with core competencies in the fields of health care, nutrition, and
high-tech materials. With annual revenue over $43 billion, Bayer is one of the largest
companies in the world. In 2010, Bayer employed 108,400 full-time employees
throughout its 302 subsidiaries around the world.
True to its own mission statement, "Science for A Better Life", Bayer invests
approximately $2.2 billion dollar annually in research and development to improve the
quality of life. Because of this strategy, Bayer has become the pioneer for many
important discoveries for the past two hundred years. The most famous discovery of all
is Aspirin. As one of the most widely used drug since its discovery in 1897, its worldwide
consumption was estimated to be 40,000 tons per year [Warner, 2002].
Bayer AG was reorganized in 2003 into three business area companies, Bayer
HealthCare, Bayer CropScience, and Bayer MaterialScience, and three service area
companies, Bayer Business Services, Bayer Technology Services, and Currenta. The
business area companies and service area companies are legally independent
corporations. These six companies are managed by Bayer AG, the parent management
holding company. This reorganization effort separates operational management from
strategic management. Bayer AG took the responsibility of strategic management while
each of the six companies took the responsibility of their respective operational
management areas.
Unlike other major pharmaceutical companies, Bayer's pharmaceutical revenue only
accounts for 62% of its total revenue. With only three blockbuster drugs, Bayer was able
to reach #14. 2010 is a forgettable year for Bayer, most of the product line did not show
much growth except Nexavar, an oncology drug. In next few years, Bayer will face stiff
competition in two out of three blockbuster drugs.
U.S court invalidated Bayer's largest blockbuster drugs, Yasmin, in 2008 which allows
Barr Laboratories to produce YAZ, a generic version of the drug, at a much lower cost.
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Betaferon, a multiple sclerosis drug and the second largest blockbuster drug of Bayer, is
projected to loss its market share in the upcoming years. In the next five years, there will
be 17 more possible entry to the multiple sclerosis market with 6 generic products (Table
3). Bayer will need to make up the possible revenue loss through new product
introduction and efficiency increase.
Fampridine Acorda
able 3 Projected MS Drug tompetitors
2u1u
1.3 Supply Chain of Bayer
Bayer's supply chain can be broken down into four modules; Product Distribution, Active
Pharmaceutical Ingredient (API) Sourcing, Production Planning, and Production Process
(Figure 2).
1.3.1 Product Distribution
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Cladribine Merck Serono 2010
FTY720 Novartis 2010
Generic Copaxone Generic Manufature 2011
Laquinimod Teva 2012
BG-12 Generic Manufacture 2012
Campath Genzyme 2012
Teriflunomide Sanofi Aventis 2013
PEG IFN B-1 a Generic Manufacture 2013
IFN Biosimilars Generic Manufacture 2013
BAF312 Novartis 2015
MN-1 66 MediciNova 2015
TV-1102 Teva 2015
Atacicept Merck Serono 2015
Daclizumab Generic Manufacture 2015
Ocrelizumab (2H7) Generic Manufacture 2015
Firategrast GSK 2015
Bayer has distribution center in six continents. There are three levels of distribution:
production facility to regional distribution facility, regional distribution facility to local
distribution center, and local distribution center to customers. When customer demand
arrives, products will be check out of the inventory at local distribution center and the
customer demand data will be recorded into sales database. This information will then
be used for demand forecast and production planning process. Regional distribution
facility will replenish the local facility while receiving replenishment from production
facility.
1.3.2 Production Planning
There are two inputs for production planning; sales forecast and sales database. Each
region's sales manager will estimate and compile next 36 months' sales forecast. This
information will be sent to demand forecast team for further analysis. Demand forecast
team will utilize actual sales database to generate statistical forecast and compare with
sales forecast from regional sales manager to determine the demand forecast for next
36 months.
This information is entered into SAP, an enterprise resource planning (ERP) system.
Advance Planner and Optimizer (APO), a key component of SAP, will conduct mix-
integer optimization using capacity and other resources constraints to determine the
production schedule. This schedule will tell production department which products need
to be produced in specific quantity at specific production cycle. Bayer practices single
production site strategy where any given product will only be produced at a specific site.
Therefore SAP does not need to determine where the product needs to be produced.
Once production schedule is generated, a bill of material (BOM) is developed for
vendors to provide material for production.
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Figure 2 Bayer Supply Chain Overview
1.3.3 API Sourcing
A drug is composed of two parts: API, the drug itself, and excipient, extra ingredient that
decides the form of the drug. API sourcing is critical to drug production. In Bayer, some
APIs are sourced from manufactures all over the world, and some are produced
internally in API facilities. API will be supplied to each production site based on BOM
generated through SAP.
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1.3.4 Production Process
Finalized production schedule generated from SAP provides production department the
products need to be produced for the production cycle. The schedule does not contain
the production sequence. Production planner will use a heuristic tool to minimize
changeover cost and produce a detail schedule with production sequence. The
production department will produce based on the detail schedule. Once production
process is finished, product will either be stored or ship out for replenishments.
1.4 Motivation
Bayer understands the importance of lean in pharmaceutical industry. A system like
SAP, put in years ago, was used to eliminate waste and increase efficiency. APO will
provide production planner information such as what to produce, when to produce, and
how much to produce. Planner will have to decide on the production sequence using a
heuristic tool to minimize the changeover cost. This process is called a cost driven
planning process.
In theory, a cost driven planning process will produce product at the lowest cost while
satisfying customer demand. But in reality, the optimal schedule was rarely achieved for
variety of reasons. The schedules are frequently suboptimal due to constraints
simplification, fixed random variables, and adjustment to the schedule. Any of the reason
mention above can cause results to deviate from optimal solution.
Another problem with cost driven planning process is that the products varies from
month to month. Consistency is the foundation of lean management. Without
consistency, continuous improvement techniques, such as Single Minute Exchange of
Die (SMED), cannot be applied. Without continuous improvement, the best schedule
SAP APO can only produce an optimal schedule in a suboptimal process. Inconsistency
also causes unnecessary pressure on production operators, planners, and other
supporting teams. A mistake due to pressure in production or planning can be costly. A
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simplified planning and production process is needed in order to create a consistent
production environment.
Production wheel, a lean tool, can be used here to simplify the planning and production
process. Instead using SAP APO to find an optimized production schedule, a fixed
sequence of production is created to minimize changeover time. Using a production
wheel, production managers will know exactly what is produced in the next production
cycle. Through frequent changeover with smaller lot size, production department will be
encouraged to improve the changeover process which promotes lean concepts and
build a foundation for continuous improvement.
In theory, production wheel is an excellent tool to improve consistency. In reality, there
are still many questions need to be answered before implementation. Bayer decided to
evaluate current system, a cost driven planning system, and future system, a production
wheel system, to answer one question: Can production wheel provide the same service
level at lower cost compares to the current system?
1.5 Methodology
The approach to this project is to provide understanding of the behavior of the systems
using computer simulation. Each system will be designed and simulated using computer
simulation software called Arena. Key Performance Indicator (KPI), such as fill rate,
cycle time, inventory level, etc. will be tracked and analyzed. The result from the
simulation will be analyzed and used to answer Bayer's questions.
This process will follow a 4 steps process:
1) Evaluate Business Characteristics - Chapter 1
2) Design, simulate, and validate current state and future state - Chapter 3 and 4
3) Analyze characteristic of state, future state - Chapter 5
4) Offer observations and recommendation - Chapter 6
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1.6 Research Scope
The scope of this project will be limited to a single unidentified facility in Germany. This
production facility produces 138 SKU in 2010 using six different APIs. Due to data
inconsistency, only 99 products will be modeled and simulated. This model will exclude
API manufacturing and sourcing process but include the production process where API
is transformed into finish goods.
This facility supplies distribution center worldwide. Therefore finish good inventory is
scattered around the world which includes production facility, regional distribution
centers, and local distribution centers. To simplify the process, this thesis will exclude
complicated pharmaceutical regulations in international trades and transportation
process between production facility and distribution centers. Therefore there will be only
one finish good inventory to supply directly to the customers (Figure 3).
Materials: 99 SKUs
Included Form: API, Bulk,
Packaged and Finished Goods
Included Process:
Forecasting, Planning,
Formulation, Filling,
Sterilizing, Drying, Optical
Control, Packaging and
Inventory Process*
Figure 3 Project Scope
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Chapter 2: Literature Review
The theme of this thesis is to evaluate overall supply chain impact of lean
methodologies, specifically production wheel, in a SAP environment. While there are
many literatures on lean in pharmaceutical industry, the integration of lean in a SAP
environment cannot be found. An extensive literature review was completed with the
purpose of understanding supply chain management, lean management, SAP system,
and modeling and simulation.
2.1 Supply Chain Literatures
Council of Supply Chain Management Professionals' (CSMP) current definition for
supply chain management is that supply chain management integrates supply and
demand management within and across companies [CSCMP, 2011]. With such broad
definition, supply chain management includes all activities from marketing department
who gather demand data to retailers who provide distribution to final consumers. A
popular model, Supply Chain Operations Reference-Model (SCOR), is more appropriate
considering the scope of this thesis.
SCOR describes supply chain in three levels of hierarchies [Stadtler et. al., 2008]. At the
first level of hierarchy, which includes plan, source, make, deliver, and return, scope of
the supply chain is determined (Figure 4). At the second level, a supply chain strategy or
configurations, such as Make-to-Stock, Make-to-Order, or a combination of the two
strategies, is determined. At the third level, business activities are derived from the
supply chain strategy determined at level two. This model can be used to describe
Bayer's supply chain.
Once the model of the supply chain is completed, it is important to measure its
performance. There are two level of performance management: system level and
component level. At system level, tools such as Economic Value Added (EVA) [Brewer
et. al., 1999] and Activity Based Costing (ABC) [Kaplan et. al., 1987] can be used to
determine the economic profit and cost structure of the entire supply chain. EVA
translates the supply chain KPIs, such as fill rate, inventory level, and cycle time, into
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financial KPIs, such as gross margin, total expenses, and current and fixed assets
(Figure 5). This is a popular tool to interpret supply chain impact for non-supply chain
professionals. On the other hand, ABC analysis determines the cost-bottleneck of the
system. This method can help lean professionals to identify focus-improvement projects.
P2: Pau rc -P3: Plaamde P4:- PMa delUe P5:Plan rtur
Deliver
Source Make
D1: Deliver stockedprdc
CL sU Sote stockedproduct M:Mae4l
Source return Deliver rei mt
Ena ee Plan Deliver Return
Figure 4 SCOR Level I and Level 2 (Stadtler et. al., 2008)
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Figure 5 Impact of Delivery Perfomance using EVA (Lambert and Pohlen, 2001)
At component level, four categories of KPI, delivery performance, supply chain
responsiveness, assets and inventories, and cost [Silrie, C., Wagner, M., Supply Chain
Analysis (2008), Springer, P37-62] can be used as benchmark when comparing different
systems. Most commonly used KPIs for delivery performance are fill rate (Equation 1),
number of stock outs, cycle time (Equation 2), and forecast measurements. Mean
absolute deviation (MAD), mean square deviation (MSD), and bias (BIAS) are the three
commonly used quantitative measurements for forecast models [Hopp et al., 2008]. Fill
rate and number of stock outs are the contributing factors for gross margin while cycle
time and forecast measurements are contributing factors for total expenses.
Improvement in either gross margin or total expenses will improve the profit-from-
operations.
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Impact of Delivery PerIfonnance
Obtne maeot unstes
- incmeas sh;W ofktndrinsr
mimandeaipdenps
1:educe 1:1hanin cosft
FillRate = 1 - BackOrderAtEndofPeriodTotalDemand
Equation I Fill Rate
CycleTime = Top
Equation 2 Cycle Time
MAD - absolute(F(t)-A(t))N
Equation 3 Mean Absolute Deviation
MSD= N (F(t)-A(t))
Equation 4 Mean Square Deviation
BIAS = Z(F(t)-A(t))N
Equation 5 Forecast BIAS
e F(t) is the forecasted value for time t
" A(t) is the actual value for time t
Supply chain responsiveness describes the ability of the supply chain to deal with
unexpected changes. Such changes can occur in raw material supply, production
capacity, and market demand. There are no specific KPIs for supply chain
responsiveness. This thesis will use the rate of change of delivery performance to
determine supply chain responsiveness.
Assets and inventory of a supply chain is another important measurement. In
accounting, common measurements for assets and inventory includes asset utilization,
inventory turnover, average inventory value, and average inventory level. This thesis will
only consider asset utilization, average inventory value, and average inventory level.
Applying EVA model, average inventory value and average inventory level are
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considered as the KPI for current asset while asset utilization is considered as the KPI
for fixed assets. Improvement in these two areas will result in capital gain.
Lastly, the supply chain cost has to be measured. Peter Bolstorff's article, "Supply Chain
Performance" [Bolstorff, 2003] suggest the total supply chain cost is the sum of order
cost, management cost, material acquisition cost, planning cost, inventory cost, IT cost,
return management cost, cost of goods sold (COGS), and SG&A cost. Due to the scope
of this project, management cost, material acquisition cost, planning cost, IT cost, return
management cost, COGS, and SG&A cost are ignored. This thesis will only consider
changeover cost and inventory holding cost. Using average inventory value, we can
determine inventory holding cost for the supply chain (Equation 6). These two costs are
part of total cost in EVA. Improvement in these two costs will improve profit-from-
operation.
InventoryHoldingCost = HoldingCostRatio* Ave arg elnventoryValue
Equation 6 Inventory Holding Cost
2.2 Lean Literatures
Lean was first mentioned in James Womack's book "The Machine that changed the
world" [Womack et. al. 1990]. The concept of lean was inspired by Eiji Toyoda, owner of
Toyota, and developed by Taiichi Ohno, widely considered as the father of lean
manufacturing. After Mr. Toyoda's visit from Ford's production facility, he felt that there
were possibilities to improve even the greatest production system of 1950s, Ford's
Production System. This became the concept of continuous improvement. Instead of
coping Ford's mass production system, Taiich and Eiji developed a new system called
Toyota Production System (TPS).
TPS, also known as the Lean Manufacturing or Lean Management, emphasizes doing
more with less. Key elements of lean management include waste reduction, stability
improvement, Just-In-Time (JIT), Jidoka, Kaizen, and Hoshin Planning [Dennis P. et. al.
2007].
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Traditionally, there are seven wastes in the lean: motion, waiting, transportation, defect,
over-processing, inventory, and over-production. Recently, a new waste, knowledge
disconnection, was added to the list. Each waste represents inefficiency of the system
and opportunity for improvement. The worst waste out of the eight wastes above is the
waste of over-production. When over-production occurred, all seven other wastes
occurred. The eight wastes are the knowledge foundation for any lean practitioner.
Lean Management implementation requires a stable work environment. It emphasizes
on waste elimination at its root cause. In an unstable system, root cause cannot be
identified. Therefore a stable environment is a prerequisite for any lean organization.
Stability need to be achieved at four levels, commonly known as the 4 Ms: Manpower,
Machine, Material, and Method. At each level, tools such as production wheel, 5S, TPM,
visual control, and work standardization can be used to improve stability.
Once stable environment is achieved, lean practitioners can implement more advance
tools such as JIT, Jidoka, and Hoshin Planning. JIT is a pull supply chain that only
produces the right product, right quantity, and right time. The upstream process is
triggered by the downstream process, and ultimately is triggered by customers. This
system was designed to minimize waste and maximizing flexibility. The prerequisite of
this system is to achieve world class quality control.
Jidoka is the Japanese word for automation. It is one of the tools that lean practitioner
can use to improve quality control. This technique will stop the production process
immediately when defects occurred. Production will not resume until the problem has
resolved. This eliminates the possibility of overproduction of defect products. Another
tool called Poka-yoke, error prevention technique, is also commonly used to provide a
fool proof process to minimize defects in production process.
The key success factor of lean management is the culture of continuous improvement.
Kaizen, the Japanese word for continuous improvement, is a concept which focuse on
small improvement projects that can be finished in short period of time. In Kaizen
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environment, employees are encouraged to generate and execute improvement ideas,
also known as grassroots projects. Other tools such as Gemba Walk can also be used
to improve Kaizen environment. A company can only call themselves a lean company
once they achieved the culture of continues improvement.
2.3 SAP Literatures
SAP stands for Systems Applications and Products in Data Procession. It is an ERP
system used by 70% of Fortune 100 companies and 50% of Fortune 500 companies
[Gartner research 2008]. Traditional modules in SAP, a.k.a SAP R/3, was modulated in
different business functions, such as Finance & Controlling, Sales & Distribution,
Material Management, Production Planning, Quality Management, Warehouse
Management, Logistics Execution, Human Resource, Project Systems, Environment
Health and Safety, and Product Life Cycle Management. In 2003, SAP AG released the
newest EPR software called mySAP Business Suite, which included all functions from
SAP R/3. The new dimension products in mySAP include Customer Relationship
Management, Supplier Relationship Management, and Supply Chain Management.
SAP Supply Chain Management (SAP SCM) includes 5 subsystems; Advanced
Planning and Optimization (APO), Forecasting and Replenishment (SAP F&R), Supply
Network Collaboration, Event Management, and Extended Warehouse Management.
SAP APO focuses on SCM which includes external partners [Knolmayer, et. al., 2009].
This subsystem contains 6 different modules: demand planning (DP), Supply Network
Planning (SNP), Supply Chain Collaboration (COL), Production Planning and Detailed
Scheduling (PP/DS), Global Available-to-Promise (ATP), Transportation Planning and
Vehicle Scheduling (TPNS), and Maintenance and Service Planning (MSP).
The APO DP module will provide an aggregated level of forecast on future demands
from sales history and sales forecast. SNP module will use the forecasted future
demand generated from DP, available resources, and production constrains to network
planning between sourcing, production, and distribution. The initial network planning
through SNP will allow partners, such as suppliers and distributors, to interact with the
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detail planning process using COL. Partners will collaborate with planners to make
adjustment in resource and constraints for future production process. This information
will then be utilized by PP/DS to determine a detail production schedule through mix-
integer optimization process. Once detail production schedule is complied, ATP will
generate due dates for sales managers to use as an estimated due date for future
orders. TPNS will handle transportation logistics, and MSP will handle production
support and maintenance logistics.
2.3 Modeling and Simulation
Modeling and simulation (M&S) is an essential tool for systems engineering. M&S is
commonly used to model complex system, such as manufacture, service, military,
transportation, and supply chain process. Instead of describing the best situation to use
M&S, Banks et. al. described 10 rules when M&S is not appropriate. Applying these 10
rules, we are able to determine M&S is an appropriate tool to use (Table 4).
M&S is a complex process. Banks et. al. provided a 12 steps systematic process to
execute this project: 1) problem formulation, 2) setting project objective, 3) data
collection, 4) model conceptualization, 5) model translation, 6) model verification, 7)
model validation, 8) experimental design, 9) model simulation and analysis, 10)
additional simulation runs, 11) documentation and reporting, and 12) implementation
[Banks et. al. 2005]. This thesis will follow this approach but will not include
implementation since that is considered out of scope.
There are many simulation languages available in the market, such as GPSS, SIMAN,
Simscript, and SLAM. They are highly flexible and powerful to execute complicated
system simulation. However, these simulation languages are difficult to present due to
lack of graphical interface. Arena provides graphical interface with the flexibility of
simulation language [Kelton et. al. 2003].
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The problem can be solved using common The problem is too complex for common
sense analysis sense analysis
The problem can be solved analytically
using a closed form The problem is too complex for closed form
It's easier to change or perform direct Direct experiments is too costly and difficult
experiments on the real to perform
The cost of the simulation exceeds
possible savings Simulation cost was justified by Bayer
There aren't proper resources available for Both MIT and Bayer will provide proper
the M&S project resources
There isn't enough time for the model There is enough time, 8 months, for M&S
results to be useful project
There is no data or not enough data for
simulation Data is not complete but enough for M&S
The model can't be verified or validated Model can be V&V with past data
Project expectations can't be met Project expectation is clear and can be met
If system behavior is too complex, or can't System behavior is complex but can be
be defined Idefined
Table 4 Ten Rules Analysis for Bayer Project (Banks et. al., 1997)
In Arena, the most commonly used model is the event-driven simulation model. The
model can be divided into four parts: 1) entity arrival, 2) system process, 3) entity
departure, and 4) simulation termination. When entity arrived to the system,
characteristic of the entity will be assigned then the entity will be transferred for process.
After process, the entity will exit the system where KPIs will be recorded. Simulation will
not stop until termination condition is met. In Arena, the KPIs will be compiled by Crystal
Report, a reporting-software developed by SAP, which can be used for analysis.
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Chapter 3: Current State
3.1 Overview
As discussed in chapter 1, there are four modules in Bayer's supply chain: product
distribution, API sourcing, production planning, and production process. Product
distribution module will not be modeled in its entirety since the project scope excluded
transportation and multiple finish goods inventory. This thesis will only consider one
finish goods inventory, and distribution process is instantaneously and directly serves
end consumer. This simplification is reasonable since bullwhip effect is minimal in
Bayer's supply chain due to practice of Vendor Management Inventory. API sourcing will
also be considered as out of scope. In this model, we will assume infinite supply of raw
material. This assumption should not affect the outcome of the simulation since API
shortage rarely happens. This model will focus on production planning and production
process.
There are four modules in Arena models: demand and production logic, production
sequence, production process, and KPI collectors (Figure 6). Product distribution and
part of the production planning are modeled in demand and production logic module. In
this module, demand is generated, and product will be check out from finish good
inventory (Figure 7).
The production sequence, part of production planning process, is modeled in a separate
module, called production sequence module. This module will look at the products in the
production queue and provide an optimal schedule to minimize the changeover cost.
Once the optimal sequence is determined, the product will be sent to production process
where product is formulated, filled, sterilized, dried, inspected, and packed. After the
product is packed, they will be check into finish goods inventory. At this time, important
KPIs will be collected for future analysis.
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Figure 7 Demand and Production Logic for Product UI
3.2 Current State Supply Chain Structure
3.2.1 Demand and Production Logic
After clearly understand the supply chain structure and project scope, the current state
model can be developed in Arena. Bayer relies on SAP to determine an optimal
schedule using mix-integer optimization, and Arena is not designed to run real time
optimization. Therefore a new schedule system has to be developed to replicate SAP's
planning process.
The schedule provided by SAP minimized overall supply chain cost using demand
forecast and other resource constraints. Demand forecast is updated in a monthly
interval. A new schedule is generated by SAP every time when demand forecast is
updated. Therefore we will assume SAP schedule is determined at the beginning of
every month.
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This type of review system with constant time interval is defined as periodic review
system. At each review, SAP triggers production if coverage time falls below the
threshold of 45 days. The coverage time is described as how long current inventory,
excluding safety stock inventory (Equation 7), will last based on the forecast. We will use
a coverage time ratio (Equation 8) to determine if production is needed. If the coverage
time ration falls below 1, production is triggered.
SafetyStockInvenotry = SDev * ServiceFador * LeadTimeFactor
Equation 7 Safety Stock Inventory
Coverage TimeRatio = CurrentInwntory-SafetiyStocnventoryNext45DaysOJDemand
Equation 8 Coverage Time Ratio
Demand forecast data is needed to calculate coverage time. Using 201 0's sales data,
each product was fit into probability distribution. The example in Figure 5 shows that
particular product follows a normal distribution with mean of 18,058 bottles and standard
deviation of 2,284.1 bottles. At 95% of confidence interval, that product will have a
monthly demand between 13,490 bottles and 20,626 bottles. In this example, the
product's demand profile fits nicely in the normal distribution. For some products, the
demand profile cannot fit into one probabilistic distribution. In that case, multiple
probability distributions were used to describe the demand profile.
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Figure 8 Example of Fitted Distribution
Two or more distributions were used to describe the products with high demand
variation. For example, product U10 cannot be described with one probability
distribution. The past data fits nicely into triangular distribution 25% of time and gamma
distribution 75% of time. In that case, we will use decision module to set demand to
triangular distribution 25% of time and gamma distribution 75% of time (Figure 9).
Actual future demand is generated at the beginning of each review period using these
distributions. Forecast demand is generated by multiplying actual future demand by the
forecast error. Historical data of forecast demand and actual sales showed that the
forecast team at Bayer has a strong bias of over forecast. The margin of over forecast
increases as the forecast gets further into future. For example, if x is the forecast error
for period 1, and y is the forecast error for period 2, then y >= x. These values were
calculated and set as the over-forecast-multiplier.
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Figure 9 Demand Generators for Product U10
At the beginning of each period, demand will be checkout from current inventory. If
inventory, including safety stock, is less than demand, backorder is generated and will
be added on top of this month's production quota. The back order products will be
shipped directly to customer without entering finish good inventory.
Production is triggered when coverage ratio is less than one. To determine the
production quantity, past production data was analyzed. The average order up to point is
90 days of coverage time. However, there are some products with coverage time much
higher than 90 days. This was caused by SAP's complicated cost optimization method.
To duplicate SAP's cost optimization characteristic, economic order quantity (EOQ)
model was used.
EOQ model is commonly used to find the perfect balance between inventory holding
cost and ordering cost (Equation 10 and 11). Holding cost was provided by Bayer while
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ordering cost is calculated using average changeover cost. This model will not include
administrative cost. Actual demand used is the actual annual demand of 2010. Actual
sales price was used as the cost per unit. EOQ was determined for all 99 SKUs.
I 2* ActualDemand*OrderingCost
O 4 HoldingCost
Equation 9 Economic Order Quantity
HoldingCost = CarryingCwt * CostPerUni
Equation 10 Holding Cost
To simulate cost optimization, the production lot size has to be greater or equals to
EOQ. However, most of the product has an average order-up-to lot size of 90 days.
Combining average order-up-to lot size with EOQ, we are able to generate a similar
production lot size compares to SAP using Equation 11.
QtyTo Pr oduce = Max(EOQ,90daysForecastDemand)
Equation 11 Quantity to Produce
3.2.2 Production Schedule
Once SAP produced the schedule, planner will use heuristic to determine production
sequence by optimizing changeover time. Changeover time depends on the current
product's product type and previous product's product type. There are a total of six
product types between 99 SKUs. To simulate this process, optimal production sequence
was determined through nearest neighbor algorithm. In production schedule module,
products will be rearranged in the order which will minimize the changeover cost.
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3.2.3 Production Process
There are five main production processes: formulation, filling, sterilization, drying, optical
control, and packaging (see Figure 10). Each process is constrained by number of
machines/lines, availability, and number of shifts (see Table 5). Space limitation is
ignored on drying station.
Figure 10 Production Process
Formulation 2 x-breakdown 3
Filling 2 x-breakdown 3
Sterilization 3 100% 3
Drying infinite 100% 3
Optical Control 2 x-breakdown 2
Packaging 2 x-breakdown 3
Table 5 Production Process
3.2.3 KPI Collectors
Arena will keep track of general statistical summary for each product, such as the
number of entity generated (number of review). KPI collectors were designed to collect
data which Arena does not track by default. The KPIs collected include individual
product fill rate, overall system fill rate, cycle time, inventory level (bottles), and inventory
value (Euros).
3.3 Model Simulation
The model was simulated with warm up period of two years before data collection
begins. This warm up period will eliminate outliers before system reaches a stable state.
To ensure the data collected is normally distributed, data is gathered and compiled in 50
replications with length of 100 years for each replication. Central limit theorem ensures
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that sufficiently large number of independent random variables will follow normal
distribution.
3.4 Validation
The result of the Arena model produced two categories of KPIs which can be used to
validate current state model: delivery performance and assets & inventories. The Arena
model's output showed less than 10% of error across all four KPIs; the fill rate and the
cycle time describe the delivery performance, the inventory level and the inventory value
describe the assets & inventories (Table 6).
Cycle Time (Hours) 68.25 68.00 0.36%
Inventory (Bottles) 1,478,708 1,577,149 6.66%
Inventory (Euros) 3,809,182 3,600,654 5.47%
Table 6 KPI Comparison between Current State and Actual Data
The simulation model's fill rate is slightly lower than the target fill rate of 99%. In reality,
the fill rate is higher because there are many tricks to manipulate a system to improve
the fill rate which is not reflected in this simulation model. For example, if a customer
ordered 500 units of product A for period 1 and there are only 200 units available in
inventory, the most common practice is to negotiate with the customer to split one order
into two orders; 200 units in period 1 and 300 units in period two. If customer accepts
the offer, then the extra 300 units of order is not consider as back order. The simulation
model did not include such options to boost fill rate; therefore, a slightly lower fill rate of
97.33% is reasonable.
The cycle time of the product reflects the average time a lot of order will spend in the
system. The data from 2010 showed us the average cycle time is 68 hours. Cycle time
yield by current state simulation model is 68.25 hours. With deviation less than 1 %, we
can conclude that the simulation model produced accurate system cycle time.
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Inventory level and inventory value are two of the most important KPIs to determine the
effectiveness of the simulation model's effort to duplicate SAP's scheduling policy.
Inventory level of the simulation model is only 6.66% higher than the actual data, and
the inventory value is 5.47% higher than the actual data. With less than 7% of error on
both inventory level and inventory value, simulation model successfully duplicated SAP's
scheduling policy. Overall, we can conclude that the simulation model is an accurate
representation of Bayer's production supply chain.
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Chapter 4: Future State
4.1 Overview
The future state Arena model is based on the current state Arena model (Figure 11).
The major difference between two states is the production sequence. Current state uses
a cost optimization approach where production sequence is determined at the beginning
of each review period to minimize changeover cost. In future state, production wheel will
determined the production sequence.
4.2 Future State Supply Chain Structure
Production wheel is a predetermined production sequence where changeover costs
were minimized. The wheel is determined in three steps provided by Bayer.
1. Use traveling salesman algorithm to determine the optimal changeover
cost between product types
2. Use traveling salesman algorithm to determine the optimal changeover
cost within each product type base on the bottle size
3. Sorted products within each bottle size by material ID
Bayer's intention is to create stability in production sequence and each product will have
dedicated machine for filling and packaging. The traveling salesman algorithm showed
that the minimal changeover cost can be achieved through two production wheels. Each
wheel will contain three product types. First wheel contains 46 SKUs while second wheel
contains 53 SKUs.
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Figure 11 Future State Model
At the beginning of each review period, future state model will start at the first product of
each wheel. If coverage time ratio for a product is under 45 days, production will be
triggered. Otherwise, production will be skipped and wheel will be turned, and next
product will go through coverage time ratio check. For example, the first wheel includes
product type 5, 4, and 1. At the beginning of the period, production logic will start
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inventory check with product type 5 and end with product type 1. The wheel will turn
clockwise, and production will follow the exact sequence the wheel turns [see Figure 12].
Figure 12 Product Wheel
In production wheel scenario, resources cannot be shared. For example, in current
state, Filling Line 1 and Filling Line 2 can provide filling process for any product. Using
production wheel, Filling Line 1 can only provide filling service for product type 1 and 6
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while Filling Line 2 provides filling service for product type 2, 3, 4, and 5. Similar
constraint exists in packaging process.
4.3 Model Simulation
The future state model is simulated with identical setup as the current state model. The
simulation model will have 2 years of warm up time and the 10 replication with length of
100 years each. The result of this model will be compared in next chapter.
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Chapter 5: Model Evaluation
5.1 Overview
In previous two chapters, we discussed the logic of current state model and future state
model. The focus of this chapter is to determine and understand the differences between
current state model and future state model. KPI comparison will be used to compare two
systems at stable state. Then we will conduct sensitivity analysis to revile detail
characteristics of both systems. This chapter will interpret and explain the KPI
differences under stable state and characteristics from sensitivity analysis.
5.2 Key Performance Indicators
The KPI comparison between current and future states has provided some interesting
insights (Table 9). Current state model outperformed future state model in terms of fill
rate, cycle time, and changeover time. However, reminding KPI such as inventory level
and inventory value is almost identical.
Fill Rate 97.33% :5.40,
Cycle Time (Hours) 68.25 78.39 14.86%
Inventory (Bottles) 1,478,708 1,427,004 3.50%
Inventory (Euros) 3,809,182 3,865,614 1.48%
Changeover (Hours) 1,169 1,487 27.23%
Table 7 KPI Comparison of Current State and Future State
5.2.1 Cost Comparison of the Two Systems
There are three costs this thesis will consider, inventory holding cost, changeover cost,
and loss of sale. The inventory holding cost, is calculated using inventory value, for
future state model is only 3.5% lower compares to the current state model. Therefore,
we can conclude that there are no significant differences in terms of inventory holding
cost between the two systems.
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When comparing changeover cost, future state is 27.23% higher compares to current
state. This suggests future state's changeover cost is approximately 27% higher as well.
However, majority of the changeover cost, labor cost for example, are sunk cost and
changeover cost is relatively small compares to inventory holding cost. We can conclude
that the difference of changeover cost between two systems is insignificant.
Lastly, future state has a fill rate that is 9.12% lower compares to current state. This
suggests that the cost for lost sales due to low fill rate is significantly higher for future
state model. Considered all three costs; we can conclude that future state model will
cost more than current state model.
5.2.2 System Utilization
Table 7 suggests current state outperformed future state in fill rate, cycle time, and
changeover time. This was caused by lack of flexibility in future state model. In
production wheel, product has dedicated production path. For example, product U30 can
only be filled at Filling Line 2 in future state. In a scenario where Filling Line 1 is
available, and product U30 is queuing behind another product on Filling Line 2, current
state model will provide the flexibility by allowing U30 to be produced in Filling Line 1
instead of waiting in the queue. However, in future state model, U30 will have to wait for
Filling Line 2 even though Filling Line 1 is available. This lack of flexibility will lead to
higher cycle time for product U30. As Filling Line 2 becomes more congested, the fill
rate for products in that line will decrease. This phenomenon, unbalance workload
between resources, can be shown through resource utilization comparison of the two
systems. In Figure 13, future state shows large deviation in terms of resource utilization
between filling lines and packaging lines (Figure 13).
Similar to fill rate and cycle time, changeover in future state was outperformed by current
state due to lack of flexibility in production sequence process. In current state,
production schedule was determined at the beginning of each production cycle based on
the products in each production cycle. In future state the production sequence is
predetermined as every product will be produced. The sequence is optimal if all products
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are produce in the production cycle. In reality, not every product will be produced in
every production cycle. When a product in the production wheel is not produced in this
cycle, this created a skips in production wheel. When the wheel skipped, the production
sequence is no longer optimal and will result in higher changeover cost.
Utilization Comparison U Current State
* Future State
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
N Current State 78.01% 94.11%94.11% 50.46%87.78% 87.78%89.44%
* Future State 83.77% 73.40% 99.37% 44.59%75.54% 91.99%96.93%
Figure 13 Resource Utilization Comparison
In summary, at the stable state, current state will outperformed future state in terms of fill
rate, cycle time, and changeover hours due to extra flexibility in resource utilization and
production sequence process. Current state also outperformed future state in terms of
changeover cost and loss of sale. Based on the stable state analysis alone, we can
conclude current state is significantly better compares to future state.
5.3 Sensitivity Analysis
Last section indicates both states perform at similar level in the category of assets and
inventories while current state outperformed future state in every other KPI due to extra
flexibility in resource utilization and production sequence process. However, last section
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did not revile any system behaviors when changes occurred. In this section, we will
conduct some sensitivity analysis to revile important characteristics of current state
model and future state model.
5.3.1 Responsiveness
The responsiveness of a system is defined, in this thesis, as how well the system can
perform under dramatic changes. For example, if a drug is promoted by Oprah Winfrey,
then the demand for that drug will increase sharply, if history prevails. A long term
strategy will allow Bayer to expand their production capacity by increase their capital
investment and labor force to meet extra demand. This analysis will only focus on short
term impact, where Bayer cannot add extra capacity to deal with demand increase. We
will test the responsiveness of supply chain under extreme condition.
Overall System Demand Increase
In first scenario, we will analyze how both systems behave when overall system demand
increased. To simulate demand increase, demand for each product is multiplied by a
multiplier, ranging from 100% to 200%. The model was simulated with warm-up period
of 1 year and simulation time of 10 years.
The results from simulation show both systems decrease at a similar rate. Using two
samples student T test, with 95% of confident level, we cannot conclusively say that the
change of fill rate in current state is different from future state. Therefore, with 95% of
confident level, we cannot conclusively say one system is more responsive to change
compares another system.
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100% 97.33% 0.00% 88.45% 0.00%
110% 94.07% -3.26% 85.17% -3.28%
120% 90.25% -3.82% 81.66% -3.51%
130% 87.24% -3.01% 77.79% -3.87%
140% 83.99% -3.25% 75.83% -1.96%
150% 79.72% -4.27% 72.29% -3.54%
160% 75.81% -3.91% 69.23% -3.06%
170% 72.79% -3.02% 65.89% -3.34%
180% 70.39% -2.40% 62.91% -2.98%
190% 68.24% -2.15% 60.24% -2.67%
200% 64.81% -3.43% 58.10% -2.14%
Table 8 Total Demand Increase Impact On Fill Rate
Random Product Type Demand Increase
In first scenario, we cannot identify any significant difference between current state and
future state's response to change in overall demand. In this scenario, we will test the
responsiveness of each system when demand increase is applied to one randomly
select product type. The model was simulated with warm-up period of 1 year and
simulation time of 10 years.
100% 98.93% 0.00% 88.45% 0.00%
110% 95.25% -3.68% 84.62% -3.83%
120% 92.94% -2.31% 83.85% -0.77%
130% 91.84% -1.10% 80.63% -3.22%
140% 90.03% -1.81% 78.47% -2.16%
150% 88.09% -1.94% 77.25% -1.22%
160% 85.55% -2.54% 75.89% -1.36%
170% 83.82% -1.73% 73.48% -2.41%
180% 81.65% -2.17% 71.42% -2.06%
190% 80.48% -1.17% 70.32% -1.10%
200% 78.80% -1.68% 69.71% -0.61%
Table 9 Random Product Type Demand Increase Impact On Fill Rate
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Similar to previous scenario, the data does not show clear sign of difference between
two systems (Table 9). Applying two samples student T test, with 95% of confident level,
we cannot conclusively say one system is more responsive to change compares another
system.
In conclusion, both systems show no significant difference in responsiveness when
overall demand increases or random product type demand increases. With 95% of
confident level, we can conclude that there are no significant differences between
responsiveness in current state and future state in both scenarios.
5.3.2 Changeover Improvement
The primary benefit of production wheel is to provide a stable environment for
changeover improvement. To analyze the effect of changeover improvement, both
systems was simulated using improved changeover time of 50% of the original
changeover time and instantaneous changeover.
The result of the simulation suggests if changeover of the future state is improved by
50%, the cycle time will improve by 17.4% and outperformed current state model (Table
10). However, current state will still be superior in terms of fill rate even if instant
changeover is achieved in future state. This phenomenon was caused by the lack of
flexibility of future state in resource utilization.
Fill Rate 97.33% 88.45% 91!.24 % 95
Cycle Time F68.25 78.39 764.74516
Table 10 Sensitivity Analysis on Changeover Improvement
In conclusion, the future state model can achieve better cycle time compares to current
state with only 50% changeover improvement. However, it cannot outperform current
state in terms of fill rate through changeover improvement. This suggests the impact on
fill rate from loss of flexibility outweighs the gain from possible changeover improvement.
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5.3.3 Forecast Improvement
SAP schedule system, current state, is a make-to-forecast system. Since future state
was derived from current state, future state is also a make-to-forecast system. Like the
name suggested, make-to-forecast systems' performance heavily depends on the
performance from forecast teams. Before we can conduct sensitivity analysis, we have
to first analyze the historical data.
Comparing 18,550 data points, over 65% of the forecast data are higher than the actual
sales data. Base on forecast data, over 65% of time, Bayer produced 26% more than
needed (excluding safety stock replenishment), and the average BIAS per product is
2430 bottles. The average production lot size has coverage time of more than 3 months.
Therefore if we estimate each production lot has an average BIAS of 9,315 bottles which
leads to approximately 420,000 bottle of over production for each production cycle
(Table 11).
Table 11 BIAS and Overproduction
After data analysis, we have to identify the impact of over forecast in both systems. To
identify the benefit if this bias should be eliminated, both systems were simulated while
setting over-forecast multiplier to 0. The model was simulated with warm-up period of 1
year and simulation time of 10 years.
The results from simulation suggest that both systems will perform better in all KPIs if
forecast bias is eliminated (Table 12). Compare to current state, future state are much
sensitive to forecast accuracy. In future state, Bayer can save approximately $29,000 in
inventory holding cost and 30% cycle time.
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Current
State $ 5,828 1.02% 0.26% 14.42%
Future State $ 28,628 4.99% 2.77% 30.30%
Table 12 Impacts on Forecast Improvement
In conclusion, forecast improvement is essential in both systems. Through elimination of
forecast BIAS, Bayer can enjoy lower holding cost, more storage space, higher
customer satisfaction, and faster production cycle. In future state the benefits will more
than double in every category compares to current state. However, this also suggests
future state is more vulnerable to forecast BIAS. An increase in forecast BIAS can be
catastrophic.
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Chapter 6: Recommendation and Project Closeout
6.1 Conclusion on Modeling Process
The previous chapters in this thesis have explained the detail modeling process. The
process has successfully delivered current state model and future state model that
outputs probabilistic system characteristics. The model utilized wide range of
probabilistic distributions to describe the distribution process, scheduling process, and
production process from historical data. In the following sections, we will discuss model
limitation, and recommendation.
6.2 Model Limitation
The current state model was validated through comparison of important system
characteristics with actual data systematic from 2010. In chapter 3, we have shown
current state model is an accurate representation of Bayer's current supply chain.
However, this model is not without compromise. Due to time constraints, assumptions
were made and some factors are ignored and simplified. In this section, we will explain
the three important factors we ignored in this model: inventory storage and work in
progress space constraint, infinite and instantaneous raw material supply replenishment,
and product life cycle.
In reality, space is an important constraint in any production and storage facility. One of
the assumptions in this model is the unlimited space for drying process. Currently,
bottleneck exists in filling process follow closely by packaging process and optical
control process. The drying process is not the bottleneck of either system. Therefore this
assumption is valid. However, if changeover is improved and production lot size is
decreased, the bottleneck might shift to drying process. In that case, this model will no
longer be valid until space constraint is added to the system.
Another important assumption in this model is the infinite and instantaneous raw
material supply replenishment. SAP has the ability to provide BOM to raw material
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supplier few months before the actual production. This allows suppliers to properly plan
their supply chain to ensure availability of raw material at the time of production. Since
raw material shortage is assumed to be a rare event, we can conclude this assumption
is valid for the purpose of this project. In the event where raw material shortage
becomes an issue, this model will no longer be valid until raw material supply chain is
included to the system.
Lastly, this model did not consider product life cycle. The model assumes that the
products maintain a stable demand. Both current state and future state exclude any
product introduction and product phase out. In this thesis, we assume that the increase
in demand from new products will be equalized by the decrease in demand of phasing-
out products. At any given time, this assumption may or may not hold. It is up to the
practitioner of this model to decide if this is a valid assumption.
These three assumptions are the most important assumptions of this model, and they
are valid assumptions for the purpose of this project. Each of the three assumptions
were discussed and approved by Bayer. However, it is still important to understand the
limitation of this simulation model especially in an environment where these assumptions
were violated. In such event, these models will no longer be valid.
6.3 Recommendation
This thesis is to evaluate the supply chain impact of the production wheel in a SAP
environment. Bayer's long term objective is to create a competitive edge in their supply
chain using Lean management. In Chapter 2, we discussed topics such as supply chain,
SAP, M&S, and Lean management. There are three steps in the roadmap to Lean
management: understand the concept of Lean, build a pro-Lean environment, and
sustain Lean through continuous improvement. The production wheel is a Lean tool
which can help lean practitioners to establish a pro-Lean/stable environment.
In Chapter 3 and 4, we explained the modeling process of current state and future state.
Current state is considered as make-to-forecast system using SAP as a technology
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enabler. Since future state is designed base on the current state model, we can
conclude future state is also a make-to-forecast system. The only difference between
two systems is the scheduling process. In current state, production sequence is different
from one production cycle to another which creates unnecessary pressure on
schedulers, operators, and other production support teams. In future state, a production
cycle is predetermined and product will follow a predetermined production path to create
stability in the system. However, this stability is not without compromise.
In Chapter 5, we compared KPIs of both systems and determined current state
outperformed future state in every KPI. This is the result of loss of flexibility in future
state. There are two flexibilities future state lost: production sequence flexibility and
resource flexibility. In current state, production sequence is determined at the beginning
of each production process. This practice ensure the optimal changeover time
throughout the system. However, future state has a predetermined production sequence
that is optimal if every product is produced in that production cycle. If a product is not
produced in that production cycle, the changeover is no longer optimal which leads
longer cycle time, lower fill rate, and more changeover time.
Compares to production sequence flexibility lost, resource flexibility lost have much
higher negative impact on KPIs. In future state, each product will have its dedicated
production path. This system does not allow product to be produced in any resource
other than the dedicated resource even if other resource is capable and available. This
will create an unbalance production workload which will lead to much longer cycle time
and significantly lower fill rate. This result suggests initial implementation of production
wheel will have significant negative impact on Bayer's supply chain. After comparing the
initial state of both models, we decide to conduct sensitivity analysis to generate some
system insights.
Through three different sensitivity analyses, we are able to identify three interesting
system characteristics. The first characteristic we identified is that future state showed
no significant difference compares to current state when demand increase globally,
increase in every product, or a locally, increase in a random product type. This suggests
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that demand increase is not affected by the flexibility lost in the future state. The second
characteristic we identified is that the changeover improvement alone cannot outperform
current state in terms of fill rate. This suggests that the loss of flexibility outweighs the
benefit from changeover improvements. The last system characteristic we identified is
that the Bayer forecast team has a strong tendency to over forecast. Through sensitivity
analysis, we are able to identify the impact of over forecast on each KPI. The result
showed future state is more sensitive to forecast BIAS compares to current state. This
suggests controlling and reducing forecast BIAS is more important in future state than
current state.
Through these system characteristics, we are able to estimate the impact of production
wheel when implemented. At the initial implementation, it is likely to see a decrease in fill
rate. It is wise to build up some inventory before production wheel implementation. The
models suggest that the production wheel cannot outperform current state through
changeover improvement alone. Therefore it is necessary for Lean teams to find other
process improvement methods to bridge the performance gap between future state and
current state. Lastly, forecast BIAS is an important issue and we are able to quantify the
impact for both systems. The result is alarming. Production wheel is much more
sensitive to forecast BIAS compares to current state. It is important for Bayer to control
and minimize forecast BIAS as much as possible.
At the beginning of this thesis, Bayer is interested in if production wheel has the ability to
provide the same service level at lower cost compares to the current system? The
answer is clear with the simulation model. Production wheel cannot out preformed
current state without improvements. With minor improvements in changeover and
elimination of forecast BIAS, production wheel model can perform at similar level
compares to current state model. Production wheel is only the first step towards lean
management. There will be other improvements lean teams at Bayer can utilize in a
stable environment. Therefore, based on the analyses of this thesis, we recommend the
implementation of production wheel system with changeover and forecast BIAS
improvements.
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